Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

ClinicalTrials.gov ID: NCT05405660

Public ClinicalTrials.gov record NCT05405660. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-ranging Study to Assess the Efficacy and Safety of CDX-0159 in Patients With Chronic Inducible Urticaria

Study identification

NCT ID
NCT05405660
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Celldex Therapeutics
Industry
Enrollment
196 participants

Conditions and interventions

Interventions

  • barzolvolimab Biological
  • Matching Placebo Drug

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 27, 2022
Primary completion
Jun 11, 2024
Completion
Sep 11, 2025
Last update posted
Nov 5, 2025

2022 – 2025

United States locations

U.S. sites
16
U.S. states
14
U.S. cities
16
Facility City State ZIP Site status
Clinical Research Center of Alabama Birmingham Alabama 35249
Allervie Clinical Research Montgomery Alabama 36106
One of a Kind Clinical Research Center, LLC Paradise Valley Arizona 85253
Little Rock Allergy & Asthma CRC Little Rock Arkansas 72205
Kern Research, Inc Bakersfield California 93301
Allergy & Asthma Consultants Redwood City California 94063
IMMUNOe Research Centers Centennial Colorado 80112
Sarasota Clinical Research Sarasota Florida 34239
Treasure Valley Medical Research Boise Idaho 83706
Dawes Fretzin Dermatology Group, LLC Indianapolis Indiana 46250
Allergy & Asthma Specialists, PSC Owensboro Kentucky 42301
Institute for Asthma and Allergy, PC/Department of Clinical Research Chevy Chase Maryland 20815
Respiratory Medicine Research Institute of Michigan, PLC Ypsilanti Michigan 48197
University of Cincinnati Cincinnati Ohio 45267
Allergy Partners of Kerrville Kerrville Texas 78028
Allergy Associates of Utah Murray Utah 84107

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05405660, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 5, 2025 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05405660 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →